Why TransMedics Stock Is Sinking Today

Why TransMedics Stock Is Sinking Today

Josh Kohn-Lindquist, The Motley Fool

Wed, August 5, 2026 at 8:37 PM GMT+3 3 min read

• TMDX -6.96%
• NVDA +4.15%

Shares of leading, next-gen organ transplant systems specialist TransMedics (NASDAQ: TMDX) are down 8% as of 1 p.m. ET Wednesday after the company reported underwhelming second-quarter earnings. Sales growth of 21% beat analysts' hopes, but adjusted net income was more than halved, falling short of expectations. While TransMedics' adjusted net income dropped from $35 million last year to $16 million in Q2 this year, it is worth noting that $19 million of this change comes from spending on a next-gen Kidney organ care system (OCS), two new clinical programs, and a manufacturing plant in Italy. Simply put, the company remains a growth stock happy to reinvest in its operations, so its earnings may be lumpy like this at times -- nothing to panic over.

All in all, it was a solid Q2 for TransMedics as:

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

• product revenue rose 16%

• service sales increased 29%

• TransMedics' owned aircraft covered 86% of National OCS Program (NOP) donations

• sales outside the U.S. jumped 26%

• liver revenue soared 27% (TMDX's largest category)

• management boosted 2026 sales guidance from 20% to 25% growth to between 22% and 25%

While TransMedics' growth rates may not be as lofty as they once were, the stock's 41% decline over the last year has it squarely on my radar for additions again, especially trading around 34 times next year's projected earnings. Furthermore, although sales growth may have slowed temporarily, TransMedics has several growth opportunities directly ahead.

First, the company's Enhance and Denovo clinical trials could restart growth within its heart and lung donation segments. These currently account for less than one-fourth of TransMedics' sales. Second, the company continues to work on a new kidney OCS, which could grant it access to "the single largest addressable segment available to us in organ transplantation in the U.S. and around the world," according to President and CEO Waleed Hassanein. This is still a couple of years out, but could be a big development for the stock.

This growth potential -- paired with ongoing expansion plans in Europe -- keeps TransMedics a buy for me after Q2's earnings.

Should you buy stock in TransMedics Group right now?

Before you buy stock in TransMedics Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $396,758!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,300,820!*

That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of August 5, 2026.

Josh Kohn-Lindquist has positions in TransMedics Group. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy.

Why TransMedics Stock Is Sinking Today was originally published by The Motley Fool